Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

950 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.
Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Kumar SK, et al. Among authors: dispenzieri a. Blood Cancer J. 2015 Aug 14;5(8):e338. doi: 10.1038/bcj.2015.60. Blood Cancer J. 2015. PMID: 26275080 Free PMC article. Clinical Trial.
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV. Kumar SK, et al. Among authors: dispenzieri a. Leukemia. 2016 Apr;30(4):995-8. doi: 10.1038/leu.2015.225. Epub 2015 Aug 14. Leukemia. 2016. PMID: 26271606 No abstract available.
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.
Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA. Chakraborty R, et al. Among authors: dispenzieri a. Leukemia. 2018 Mar;32(3):712-718. doi: 10.1038/leu.2017.256. Epub 2017 Aug 14. Leukemia. 2018. PMID: 28848227
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma.
Cook J, Johnson I, Higgins A, Sidana S, Warsame R, Gonsalves W, Gertz MA, Buadi F, Lacy M, Kapoor P, Dispenzieri A, Kourelis T, Dingli D, Fonder A, Hayman S, Hobbs M, Hwa YL, Kyle R, Leung N, Go R, Rajkumar VS, Kumar S. Cook J, et al. Among authors: dispenzieri a. Am J Hematol. 2021 Mar 1;96(3):330-337. doi: 10.1002/ajh.26074. Epub 2021 Jan 13. Am J Hematol. 2021. PMID: 33326116 Free article.
Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma.
Fonseca R, Hoyer JD, Aguayo P, Jalal SM, Ahmann GJ, Rajkumar SV, Witzig TE, Lacy MQ, Dispenzieri A, Gertz MA, Kyle RA, Greipp PR. Fonseca R, et al. Among authors: dispenzieri a. Leuk Lymphoma. 1999 Nov;35(5-6):599-605. doi: 10.1080/10428199909169625. Leuk Lymphoma. 1999. PMID: 10609798
Prognostic value of bone marrow angiogenesis in multiple myeloma.
Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Rajkumar SV, et al. Among authors: dispenzieri a. Clin Cancer Res. 2000 Aug;6(8):3111-6. Clin Cancer Res. 2000. PMID: 10955791
950 results